Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Engagement of immune effector cells by trastuzumab induces HER2/ERBB2 downregulation in cancer cells through STAT1 activation.

Shi Y, Fan X, Meng W, Deng H, Zhang N, An Z.

Breast Cancer Res. 2014 Apr 2;16(2):R33. doi: 10.1186/bcr3637.

2.

Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.

García-Parra J, Dalmases A, Morancho B, Arpí O, Menendez S, Sabbaghi M, Zazo S, Chamizo C, Madoz J, Eroles P, Servitja S, Tusquets I, Yelamos J, Lluch A, Arribas J, Rojo F, Rovira A, Albanell J.

Eur J Cancer. 2014 Oct;50(15):2725-34. doi: 10.1016/j.ejca.2014.07.004.

PMID:
25128455
3.

A phase I study of interleukin 12 with trastuzumab in patients with human epidermal growth factor receptor-2-overexpressing malignancies: analysis of sustained interferon gamma production in a subset of patients.

Parihar R, Nadella P, Lewis A, Jensen R, De Hoff C, Dierksheide JE, VanBuskirk AM, Magro CM, Young DC, Shapiro CL, Carson WE 3rd.

Clin Cancer Res. 2004 Aug 1;10(15):5027-37.

4.

A single proteolytic cleavage within the lower hinge of trastuzumab reduces immune effector function and in vivo efficacy.

Fan X, Brezski RJ, Fa M, Deng H, Oberholtzer A, Gonzalez A, Dubinsky WP, Strohl WR, Jordan RE, Zhang N, An Z.

Breast Cancer Res. 2012 Aug 8;14(4):R116. doi: 10.1186/bcr3240.

5.
6.

Therapeutic targeting of erbB3 with MM-121/SAR256212 enhances antitumor activity of paclitaxel against erbB2-overexpressing breast cancer.

Wang S, Huang J, Lyu H, Cai B, Yang X, Li F, Tan J, Edgerton SM, Thor AD, Lee CK, Liu B.

Breast Cancer Res. 2013;15(5):R101.

7.

Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.

Zhang C, Duan X, Xu L, Ye J, Zhao J, Liu Y.

Breast Cancer Res Treat. 2012 Dec;136(3):739-48. doi: 10.1007/s10549-012-2316-x.

PMID:
23117856
8.

Antitumor activity of a combination of trastuzumab (Herceptin) and oral fluoropyrimidine S-1 on human epidermal growth factor receptor 2-overexpressing pancreatic cancer.

Saeki H, Yanoma S, Takemiya S, Sugimasa Y, Akaike M, Yukawa N, Rino Y, Imada T.

Oncol Rep. 2007 Aug;18(2):433-9.

PMID:
17611667
9.

Antitumor activity of a monoclonal antibody targeting major histocompatibility complex class I-Her2 peptide complexes.

Jain R, Rawat A, Verma B, Markiewski MM, Weidanz JA.

J Natl Cancer Inst. 2013 Feb 6;105(3):202-18. doi: 10.1093/jnci/djs521.

10.

Downregulation of Erbin in Her2-overexpressing breast cancer cells promotes cell migration and induces trastuzumab resistance.

Liu D, Shi M, Duan C, Chen H, Hu Y, Yang Z, Duan H, Guo N.

Mol Immunol. 2013 Nov;56(1-2):104-12. doi: 10.1016/j.molimm.2013.04.007.

PMID:
23711387
11.

Dual blockade of HER2 in HER2-overexpressing tumor cells does not completely eliminate HER3 function.

Garrett JT, Sutton CR, Kuba MG, Cook RS, Arteaga CL.

Clin Cancer Res. 2013 Feb 1;19(3):610-9. doi: 10.1158/1078-0432.CCR-12-2024.

13.

Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells.

Hamano S, Mori Y, Aoyama M, Kataoka H, Tanaka M, Ebi M, Kubota E, Mizoshita T, Tanida S, Johnston RN, Asai K, Joh T.

Cancer Lett. 2015 Jan 28;356(2 Pt B):846-54. doi: 10.1016/j.canlet.2014.10.046.

PMID:
25444894
14.

Construction and evaluation of a novel humanized HER2-specific chimeric receptor.

Sun M, Shi H, Liu C, Liu J, Liu X, Sun Y.

Breast Cancer Res. 2014 Jun 11;16(3):R61. doi: 10.1186/bcr3674.

15.

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation.

Wang YC, Morrison G, Gillihan R, Guo J, Ward RM, Fu X, Botero MF, Healy NA, Hilsenbeck SG, Phillips GL, Chamness GC, Rimawi MF, Osborne CK, Schiff R.

Breast Cancer Res. 2011;13(6):R121. doi: 10.1186/bcr3067.

16.

Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer.

Le XF, Almeida MI, Mao W, Spizzo R, Rossi S, Nicoloso MS, Zhang S, Wu Y, Calin GA, Bast RC Jr.

PLoS One. 2012;7(7):e41170. doi: 10.1371/journal.pone.0041170.

17.

Targeting the MUC1-C oncoprotein downregulates HER2 activation and abrogates trastuzumab resistance in breast cancer cells.

Raina D, Uchida Y, Kharbanda A, Rajabi H, Panchamoorthy G, Jin C, Kharbanda S, Scaltriti M, Baselga J, Kufe D.

Oncogene. 2014 Jun 26;33(26):3422-31. doi: 10.1038/onc.2013.308.

18.

Trastuzumab triggers phagocytic killing of high HER2 cancer cells in vitro and in vivo by interaction with Fcγ receptors on macrophages.

Shi Y, Fan X, Deng H, Brezski RJ, Rycyzyn M, Jordan RE, Strohl WR, Zou Q, Zhang N, An Z.

J Immunol. 2015 May 1;194(9):4379-86. doi: 10.4049/jimmunol.1402891.

19.

Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models.

Gupta P, Srivastava SK.

BMC Med. 2012 Jul 24;10:80. doi: 10.1186/1741-7015-10-80.

20.

A class I histone deacetylase inhibitor, entinostat, enhances lapatinib efficacy in HER2-overexpressing breast cancer cells through FOXO3-mediated Bim1 expression.

Lee J, Bartholomeusz C, Mansour O, Humphries J, Hortobagyi GN, Ordentlich P, Ueno NT.

Breast Cancer Res Treat. 2014 Jul;146(2):259-72. doi: 10.1007/s10549-014-3014-7.

Items per page

Supplemental Content

Support Center